NLS Pharmaceutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for NLS Pharmaceutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	23.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

NLS Pharmaceutics gets delisting determination letter from Nasdaq

Oct 05

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

Sep 27

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

Jul 28

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

Mar 04

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

Nov 12

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NLS Pharmaceutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:NLSP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	N/A	-12	-10	-10	N/A
9/30/2023	N/A	-14	-12	-12	N/A
6/30/2023	N/A	-15	-14	-14	N/A
3/31/2023	N/A	-16	-14	-14	N/A
12/31/2022	N/A	-16	-14	-14	N/A
9/30/2022	N/A	-16	-13	-13	N/A
6/30/2022	N/A	-16	-13	-13	N/A
3/31/2022	N/A	-14	-14	-14	N/A
12/31/2021	N/A	-12	-15	-15	N/A
9/30/2021	N/A	-9	N/A	N/A	N/A
6/30/2021	N/A	-6	-10	-10	N/A
3/31/2021	N/A	-5	-5	-5	N/A
12/31/2020	N/A	-3	-1	-1	N/A
9/30/2020	N/A	-3	N/A	N/A	N/A
6/30/2020	N/A	-3	-1	-1	N/A
3/31/2020	N/A	-4	-1	-1	N/A
12/31/2019	N/A	-5	0	0	N/A
9/30/2019	N/A	-6	N/A	N/A	N/A
6/30/2019	N/A	-6	0	0	N/A
3/31/2019	N/A	-6	-2	-2	N/A
12/31/2018	N/A	-5	-3	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NLSP's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if NLSP's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if NLSP's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if NLSP's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if NLSP's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NLSP's Return on Equity is forecast to be high in 3 years time

NLS Pharmaceutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$8.63

Price target decreased to US$7.50

Recent updates

NLS Pharmaceutics Ltd. announced delayed 20-F filing

NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding

NLS Pharmaceutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.75 million.

NLS Pharmaceutics Ltd. has filed a Follow-on Equity Offering in the amount of $1.75 million.

Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance

NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol

NLS Pharmaceutics Ltd. Approves Board Appointments

NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol

NLS Pharmaceutics AG, Annual General Meeting, Jun 30, 2023

New major risk - Shareholder dilution

NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer

NLS Pharmaceutics Ltd. Announces the Resignation of Chad Hellmann as Chief Financial Officer

NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy

NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement

NLS Pharmaceutics Ltd. Announces New in Vitro Study Results Demonstrating the Agonist Effect of Mazindol ER At the Orexin-2 Receptor

NLS Pharmaceutics Ltd Announces an R&D Update Webcast to Review It’S Growing Portfolio of Pre-Clinical Compounds

NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037

NLS Pharmaceutics AG announced that it expects to receive $30 million in funding from BVF Partners L.P.

NLS Pharmaceutics AG Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder

NLS Pharmaceutics Ltd. Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe

NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice

NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy

NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq

NLS Pharmaceutics gets delisting determination letter from Nasdaq

NLS Pharmaceutics Ltd. Announces Positive Top-Line Results from Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate

NLS Pharmaceutics Ltd. Announces Management Changes

Price target decreased to US$8.63

NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders

NLS Pharmaceutics Ltd. Announces Positive Opinion from European Regulators to Grant Orphan Drug Designation for Mazindol ER in Idiopathic Hypersomnia

NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification

NLS Pharmaceutics AG Appoints Chad C. Hellmann as Chief Financial Officer

NLS Pharmaceutics AG, Annual General Meeting, May 31, 2022

Price target decreased to US$7.50

NLS Pharmaceutics AG Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER

Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation

NLS Pharmaceutics to Present Interim Top-Line Data for Quilience® (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky

NLS Pharmaceutics Announces New Study Data Confirming Mazindol's Unique Orexin Pathway Activation for Treating Narcolepsy

NLS Pharmaceutics AG announced delayed 20-F filing

NLS Pharmaceutics AG Obtains License to Full Regulatory Data Package and Proprietary Know-How for Sanorex

NLS Pharmaceutics AG Announces Change in Company’s Executive Management Team

Independent Director has left the company

NLS Pharmaceutics AG Announces Resignation of Pascal Brenneisen as A Member of the Board of Director

NLS Pharmaceutics Ltd. Approves Board and Committee Appointments

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies